Navigation Links
Awards for Drug Discovery Research for Frontotemporal Degeneration Announced
Date:3/7/2012

NEW YORK, March 7, 2012 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) announced today the recipients of their fifth annual research award, Frontotemporal Degeneration Drug Discovery Program.  The goal of the program is to accelerate the development of novel therapies for frontotemporal degeneration (FTD). 

The ADDF/AFTD program awarded $300,000 to three academic scientists developing biomarkers for FTD. The award winners are: Adam Boxer, MD, PhD, University of California, San Francisco; William Seeley, MD, University of California, San Francisco; and Charlotte Teunissen, PhD, VU University Medical Center in Amsterdam, Netherlands.  An independent panel of 7 experts from the ADDF's Scientific Review Board and AFTD's Medical Advisory Council evaluated 15 applications submitted from around the world.  

"To develop effective treatments for FTD, biomarkers are crucially needed to select appropriate patients for clinical trials and to monitor responses to treatments," said Howard Fillit, MD, ADDF Executive Director.  "Yet, there are currently no effective biomarkers available.  We are optimistic that these three programs will fulfill this unmet need and help advance drug discovery efforts for FTD."    

FTD is a devastating form of dementia characterized by profound changes in behavior, personality, language and movement. It is the second most common cause of dementia under the age of 60 years, most frequently having its onset between the ages of 40 and 65.  As with Alzheimer's disease, there are no drugs to treat, prevent or cure FTD. 

"We continue to be very pleased with the quality of applications for this program," said Susan L-J Dickinson, AFTD Executive Director. "This year's recipients are all engaged in research that offers both caregivers and patients the optimism they need to face the challenges of living with FTD. We are proud to continue our partnership with ADDF to support their work and the hope it brings to those suffering from this terrible disease."

The ADDF/AFTD Award Program has provided a total of $1,905,000 to 19 research projects since 2007.  The ADDF and AFTD are continuing their partnership in 2012 and invite applications for novel drug discovery programs for FTD.  A total of $300,000 is available.  The deadline for submission is September 20, 2012.  Application details are available on the ADDF website: www.alzdiscovery.org.

About the Alzheimer's Drug Discovery Foundation
The mission of the Alzheimer's Drug Discovery Foundation (ADDF) is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. The ADDF has granted more than $51 million to fund over 370 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries.  For more information about the ADDF, please visit www.alzdiscovery.org.

About the Association for Frontotemporal Degeneration (AFTD)
The Association for Frontotemporal Degeneration (AFTD) is a not-for-profit organization created in 2002, to advocate for more funding into the causes and treatments for frontotemporal degeneration (FTD), as well as to provide caregivers and patients with a central place to find information and support.  AFTD is the resource people turn to for accurate information about FTD, support groups and resources regarding care, research and FTD education conferences.

In addition to providing funding for this drug discovery program, AFTD continues to fund basic and clinical research that is essential to improving our understanding of this relatively rare, but significant disease. For more information about AFTD, visit www.theaftd.org.

 

 

 

 


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
2. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
3. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
4. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
5. Small Business Innovation Research Program Awards Grant to Biomoda
6. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
7. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
8. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
9. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
10. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
11. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
(Date:3/23/2017)... 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or ... pharmaceutical company, is pleased to announce that its ... from the U.S. Food and Drug Administration (FDA) ... for tetrabenazine tablets in the 12.5 mg and ... a generic equivalent of the branded product Xenazine ...
(Date:3/23/2017)... , March 23, 2017   Casetabs , the ... native mobile app for the iPhone. With this new ... coordination and communication for physician offices, ambulatory surgery centers ... app offers iPhone users even faster, more reliable access ... it even easier to connect care teams so that ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality ... 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. ... not only to the association, but also to the Health Care Quality and Patient ...
(Date:3/23/2017)... ... March 23, 2017 , ... The founders of Dr. ... as winners of American Dreams & Good Housekeeping Seal Initiative, a nationwide search ... and Good Housekeeping. , Steven Wang, MD ., a renowned dermatologist and ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
(Date:3/23/2017)... Rey, CA (PRWEB) , ... March 23, 2017 ... ... its customizable coding audit software solution, iCode Assurance, at HCCA’s 21st annual Compliance ... optimizes and accelerates the coding audit process for all medical chart types with ...
(Date:3/23/2017)... ... , ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous ... Bonetta Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures ... Rose‘s new book presents actual events in the life of her family, which validate ...
Breaking Medicine News(10 mins):